Electra Therapeutics posts Q3 2026 loss of $23.9 million and EPS of –$3.47
Electra Therapeutics reported no revenue for the quarter ended September 30, 2026 and a net loss of $23.93 million, wider than the $18.09 million loss a year earlier. Diluted GAAP EPS was –$3.47, compared with a loss of $616.86 per share in the prior year. Research‑and‑development spending rose to $17.3 million, while direct program costs for the Ipsoprubart trial increased sharply. The company said its cash, cash equivalents and marketable securities as of September 30, 2026 are expected to fund operations into 2029.
Why it matters
The widened loss and higher R&D outlays reduce short‑term profitability but the extended cash runway gives the company financial flexibility to continue its clinical programs through 2029, according to the filing.
Key facts
- 1Net loss attributable to common stockholders was $23.93 million for the quarter. tradingview.com
- 2Net loss in the prior year quarter was $18.09 million. tradingview.com
- 3Diluted GAAP EPS was –$3.47 for the quarter. tradingview.com
- 4Diluted GAAP EPS in the prior year quarter was –$616.86. tradingview.com
- 5R&D expenses increased to $17.3 million from $14.0 million year‑over‑year. seekingalpha.com
- 6Cash, cash equivalents and marketable securities as of September 30, 2026 are expected to fund operations into 2029. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.